Pre- and neonatal screening of hemoglobinopathies: a prospective study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26283

Enrollment

2000

Registered

2006-01-31

Start date

2006-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoglobinopathies

Interventions

Unselected group of pregnant females (n = 1000) and a group of newborns (n = 1000) will be screened for hemoglobinopathies.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pregnant females before the 16th week of pregancy and newborns. 2. Informed consent.

Exclusion criteria

Exclusion criteria: Known hemoglobinopathy.

Design outcomes

Primary

Measure	Time frame
Carrier frequence of hemoglobinopathies.	—

Secondary

Measure	Time frame
1. Serum ferritin; 2. Compliance to prenatal testing; 3. Cost-Effectiveness.	—

Contacts

Public ContactJ.L.H. Kerkhoffs

HagaHospital, Leyweg 275

J.Kerkhoffs@hagaziekenhuis.nl+31 (0)70 3592004

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)